Where Global Innovation
and Capital Meet
Sectors Consumer University Energy Financial Healthcare Industrial IT Media Services Telecoms Transport The Art of CVC Startups

Page 227

Verily invests in Mammoth $45m series B

Alphabet unit Verily has taken part in an oversubscribed series B round that will fund Mammoth Biosciences' expansion from diagnostics to gene editing and drug development.

Jan 31, 2020

Waters helps $18m flow to RedShift

Waters Corporation reinvested in the protein characterisation technology producer through an oversubscribed round that will fund innovation and expansion.

Jan 31, 2020

Schrödinger shoots for $160m in IPO

Wuxi AppTec and Alphabet are in line to exit the molecule-discovery software provider, which has set the range for its initial public offering.

Jan 28, 2020

Quench Bio pinches $50m in series A

AbbVie Ventures took a board seat through its contribution to the round, closed as the inflammatory disease therapy developer emerged from stealth.

Jan 28, 2020

Merck helps iOnctura mark series A round

Merck Group spinoff iOnctura will put the $18.7m it raised in the M Ventures-backed round into a clinical trial for its solid tumour therapy.

Jan 28, 2020

AbbVie alumnus Brun moves to Horizon

Scott Brun, who headed AbbVie Ventures until last April, has taken on an R&D advisory role at pharmaceutical company Horizon Therapeutics.

Jan 27, 2020

Corporate venturing deal net: 20-24 January 2020

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Jan 24, 2020

Socially Determined works out series A funding

3M, CareFirst BlueCross BlueShield, Lafayette General Health, OSF Healthcare and ProMedica all invested as the healthcare technology provider closed an $11.1m round.

Jan 22, 2020

Revolution Medicines to rule with $100m IPO

Sanofi is in line for an exit as Revolution Medicines files for a $100m initial public offering on the Nasdaq Global Market.

Jan 22, 2020

HepaRegenix heaps on $12.2m

University Hospital Tübingen's liver disease treatment spinout HepaRegenix has raised $21.6m in all following a series B round that featured Novo and Boehringer Ingelheim.

Jan 22, 2020

© 2024 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here